CTRI/2020/05/025337尚未招募2 期
A Phase-II, Open Label, Randomized Controlled Trial Of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment In Hospitalized Patients With Pneumonia Due To SARS-CoV-2 (Covid-19)
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Male and non-pregnant female patients
- •2 Positive reverse-transcriptaseâ??polymerase polymerase chain-reaction (RT-PCR) in a diagnostic specimen
- •3 Pneumonia confirmed by chest imaging
- •4 Oxygen saturation (Sao2) of 94% or less while they were breathing ambient air
- •5 Either normal levels of haematological, liver and renal functions, and electrolytes OR no worse than Grade 3 (CTCAE Version 5.0) abnormalities in any of these parameters.
- •6 Patients with high blood sugar or glycosylated haemoglobin, of any degree will be eligible
- •7 Arterial blood gas, if done, could have abnormal values of pH, PO2, PCO2 and bicarbonate levels
排除标准
- •Asymptomatic or only mildly symptomatic
研究者
相似试验
尚未招募
2 期
Randomized Controlled Trial Of Resveretrol-Copper OR Sodium-Copper-Chlorophyllin Versus Standard Treatment In Severe Covid-19 Cancer Patients.CTRI/2020/07/026514Tata Memorial Centre
尚未招募
2 期
A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated ComplicationsCTRI/2020/04/024915Max Super Speciality Hospital A Unit of Devki Devi Foundation
尚未招募
不适用
A Clinical Trial to Assess the Safety and Efficacy of Convalescent Plasma in Severe Covid-19 patients.CTRI/2020/05/025346Government of TamilNadu
已完成
2 期
Study to assess the efficacy and safety of convalescent plasma in moderate COVID-19 disease.CTRI/2020/04/024775Indian Council Of Medical Research464
进行中（未招募）
不适用
A Controlled, Randomized, Open label Phase II Trial to Evaluate Safety and Efficacy of a 1st line Combination Treatment with Weekly Infusion of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG®-1) in Three Dose Levels Compared with Gemcitabine Monotherapy in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas - N/AEUCTR2005-000666-39-SEMediGene AG200